SCHEMBL23900455

SCHEMBL23900455

O=C(COc1nc(=O)[nH]c2ccccc12)NC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.50
▸ CNR2 P34972 6/20 0.49
▸ CNR1 P21554 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ HPGD P15428 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ DHODH Q02127 1/20 0.45
▸ PDE2A O00408 1/20 0.45
▸ PDE3B Q13370 1/20 0.45
▸ PDE3A Q14432 1/20 0.45
▸ P2RY12 Q9H244 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ MAPT P10636 1/20 0.43
▸ G6PD P11413 1/20 0.43
▸ PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30361612 1.00 ALDH1A1 (0.50) ALDH1A1CNR2CNR1POLBCASP7
SCHEMBL23900368 0.78 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1HPGDKDM4E
SCHEMBL25138659 0.78 LMNA (0.41) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL23900376 0.77 ALDH1A1 (0.48) ALDH1A1CNR2CNR1KMT2AMEN1
SCHEMBL23900367 0.76 PDE3B (0.42) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL23900313 0.76 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HPGDKDM4E
SCHEMBL23884280 0.75 ALDH1A1 (0.41) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL23900446 0.75 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1HPGDKDM4E
SCHEMBL30361625 0.75 DHODH (0.54) ALDH1A1CNR1KMT2AMEN1HPGD
SCHEMBL23900449 0.75 ALDH1A1 (0.45) ALDH1A1POLBKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2024-03-19 — — US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 — — US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 — — US disclosed
CN-115916175-A Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses 南方研究院 2023-04-04 — — CN disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 — — US disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 — — US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 — — US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 — — US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 — — US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 — — US disclosed
WO-2021203048-A1 NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES SOUTHERN RESEARCH INSTITUTE (US) 2021-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885CNR2 4380/4885CNR1 4578/4885
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885CNR2 4380/4885CNR1 4578/4885
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885CNR2 4380/4885CNR1 4578/4885
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885CNR2 4380/4885CNR1 4578/4885
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 589/4885CNR2 4247/4885CNR1 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback